Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285:2508–2509.
2.
LiuJ, SemposCT, DonahueRP, et al.Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol, 2006; 98:1363–1368.
3.
RenJ, GrundySM, LiuJ, et al.Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: The results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis, 2010; 211:327–332.
4.
BoekholdtS, ArsenaultBJ, MoraS, et al.Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A Meta-analysis. JAMA, 2012; 307:1302–1309.
5.
Expert Dyslipidemia Panel, GrundySM. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. J Clin Lipidol, 2013; 7:561–565.
6.
KnowlerWC, Barrett-ConnorE, FowlerSE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346:393–403.
7.
Look AHEAD Research Group, WingRR, BolinP, BrancatiFL, et al.Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 2013; 369:145–154.
8.
KimM, TanakaK. Non-high-density lipoprotein cholesterol changes in middle-aged obese men with and without metabolic syndrome during weight loss. Metab Syndr Relat Disord, 2014; 12:464–471.
9.
McLaughlinT, AbbasiF, ChealK, et al.Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med, 2003; 139:802–809.
10.
LiuA, ReavenGM. Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome?. Nutr Metab Cardiovasc Dis, 2013; 23:1122–1127.
11.
CuiY, BlumenthalRS, FlawsJA, et al.Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 2001; 16:1413–1419.
12.
BittnerV, HardisonR, KelseySF, et al.Non-high-density lipoprotein-cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation, 2002; 106:2537–2542.
13.
JiangR, SchulzeMB, LiT, et al.Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care, 2004; 27:1991–1997.
14.
LuW, ResnickHE, JablonskiKA, et al.Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care, 2003; 26:16–23.
15.
LiC, FordES, McBridePE, et al.Non-high-density lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12–19 years. J Pediatr, 2011; 158:201–207.
16.
LangstedA, FreibergJJ, NordestgaardBG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation, 2008; 118:2047–2056.
17.
Emerging Risk Factors Collaboration, Di AngelantonioE, SarwarN, PerryP, et al.Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302:1993–2000.
